Strong revenue growth as of the end of September at +12.6% and +8.6% at constant exchange rates and scope. 2024 targets maintained.

The board of directors announces a capital reduction through cancellation of treasury shares

●    Exceptional business momentum in the first half, with revenue up 16.1% at constant exchange rates

●    Strong growth in adjusted current operating income1 
      ○ +3.4 points compared with 2023 to reach a record level at 21.4% of revenue

●    2024 targets confirmed  
      ○    Revenue growth expected between 7% and 9% at constant exchange rates and scope
      ○    Adjusted current operating income1 expected to be around 16% compared with 15.1% in 2023

Exceptional first-half momentum (+16.2% at constant exchange rates) driven by all regions

Exceptional first-half growth and guidance raised for 2024

Virbac finalizes minority shares’ acquisition of Globion, an Indian poultry vaccines specialistOn June 21, we finalized the acquisition of Globion's minority shares, bringing our stake to 100%. As planned, this transaction follows the acquisition of a 74% majority stake concluded on November 1, 2023.

Building on the momentum of the second half of 2023, strong first-quarter revenue growth of +10.8% at constant exchange rates

On April 1, we successfully completed the acquisition of Sasaeah. This strategic acquisition brings Virbac a leadership position in the farm animal vaccines market in Japan, notably in the cattle segment, and a large portfolio of pharmaceutical products for all the major species.

Virbac announces that it has signed a definitive agreement with ORIX Corporation for the acquisition of its animal health subsidiary Sasaeah for an enterprise value of approximately €280 million.

Annual revenue growth of +4.9% thanks to record fourth-quarter activity at +11.5%